ASCO 2013 Gu Intro

Article

Cancer Network presents exclusive coverage from the American Society of Clinical Oncology (ASCO) 2013 Genitourinary Cancers Symposium. Check out the stories below for write-ups of the most important information to come out of this year's event.

Cancer Network presents exclusive coverage from the American Society of Clinical Oncology (ASCO) 2013 Genitourinary Cancers Symposium. Check out the stories below for write-ups of the most important information to come out of this year's event.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Related Content
Understanding Palliative and End-Of-Life Care in Oncology

Understanding Palliative and End-Of-Life Care in Oncology

Julie M. Vose, MD, MBA
September 16th 2025
Article
Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 16th 2025
Podcast
While the trial enrolled patients with renal cell carcinoma and ovarian cancer, the component of the trial including those with renal cell carcinoma was discontinued.

The FDA Grants BTD to R-DXd in Pretreated Gynecologic Cancers

Tim Cortese
September 16th 2025
Article
A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 16th 2025
Podcast
Numerically higher ORRs were reported in those who received treatment in the second line vs third line, in those with a CTFI of 90 days or more, and those without CNS metastasis.

Lurbinectedin Yields Responses in Various ES-SCLC Subgroups

Tim Cortese
September 16th 2025
Article
Ateganosine plus cemiplimab was well tolerated in patients with heavily pretreated advanced NSCLC, with most adverse effects grades 1/2 in severity.

Ateganosine Combo Exhibits Favorable Efficacy vs SOC in Advanced NSCLC

Roman Fabbricatore
September 16th 2025
Article